Acute uncomplicated cystitis is a prevalent outpatient condition \[[@CIT0001], [@CIT0002]\]. It is estimated that there are approximately 6--8 million annual visits to a physician or clinic by patients for treatment of an acute uncomplicated cystitis event \[[@CIT0003], [@CIT0004]\]. Treatment guidelines for acute uncomplicated cystitis in premenopausal, nonpregnant women are well defined in international guidelines \[[@CIT0002]\]. In these international guidelines, empiric treatment recommendations are provided, but these empiric recommendations are accompanied by the caveat that empiric antibiotic selection should be guided by local organism susceptibility data and patient-specific risk factors.

Although treatment selection for acute uncomplicated cystitis was straightforward in the past, management of these conditions has been complicated by reports of rising antibiotic resistance rates for several key urinary pathogens. It is important to note that much of the data that describe rising rates of resistance for uncomplicated cystitis pathogens were derived from hospitalized inpatients with urinary tract infections. Data that describe outpatient resistance rates are consistent with published inpatient reports but are limited \[[@CIT0005]\]. It is also unclear if resistance rates among acute uncomplicated cystitis pathogens are applicable to all age groups, and to both men and women. Given these gaps in the literature, this study sought to describe the prevalence and resistance patterns of urinary pathogens in New York State in the outpatient setting. The intent was to use these data to help inform treatment decisions for patients who present with uncomplicated cystitis in the outpatient setting and to assess the appropriateness of empiric treatment recommendations found in national guidelines for New York State.

METHODS {#s1}
=======

A retrospective analysis was conducted on all urine cultures received from outpatient settings (defined as physician offices or outpatient clinics), with antimicrobial susceptibility testing performed from January 1, 2016, to December 31, 2016, at a major clinical microbiology reference laboratory (Quest Diagnostics Laboratory, Teterboro, NJ). As antimicrobial testing is not routinely recommended for *Streptococcus agalactiae* and *Staphylococcus saprophyticus,* these organisms were not included in the analysis. Data from 17 New York State counties were included in the overall sample ([Table 1](#T1){ref-type="table"}). Urine cultures demonstrating 1 or 2 bacterial isolates at \>10^5^ colony-forming units/mL were included (only the first reported isolate from dual infections was included). In accordance with standards for summarizing antimicrobial susceptibilities for antibiograms, each species required a minimum of 30 isolates for inclusion in antimicrobial susceptibility estimates.

###### 

Summary of Urinary Isolate Antibiotic Susceptibility From New York State

  Microorganism                                     N^a^     Ampicillin   Ceftazidime   Cefazolin   Ciprofloxacin   Nitrofurantoin   Pip-Tazo   Tobramycin   TMP-SMX   Tetracycline
  ------------------------------------------------- -------- ------------ ------------- ----------- --------------- ---------------- ---------- ------------ --------- --------------
  Overall^b^                                                                                                                                                           
   Gram-negative                                                                                                                                                       
  *  Citrobacter diversus*                          933                   100                       99              90               99         100          99        
  *  Citrobacter freundii*                          316                   93                        95              95               94         98           85        
  *  Enterobacter aerogenes*                        785                   93                        99              30               97         100          99        
  *  Enterobacter cloacae*                          404                   91                        94              44                          96           86        
  *  Escherichia coli*                              50 900   53           99            95          78              97               97         90           73        
  *  Klebsiella pneumoniae*                         7734                  100           98          95              42               95         96           90        
  *  Proteus mirabilis*                             3389     79           99            91          90                               100        95           87        
  *  Providencia rettgeri*                          43                    93                        85                               95                                
  *  Pseudomonas aeruginosa*                        1051                  94                        76                               92         95                     
  *  Serratia marcescens*                           264                   100                       98                                          88           97        
  *  Stenotrophomonas maltophila*                   53                                                                                                       100       
   Gram-positive                                                                                                                                                       
    Methicillin-sensitive *Staphylococcus aureus*   825                                             85              98                                       98        89
    Methicillin-resistant *Staphylococcus aureus*   326                                             25              97                                       96        83
    Vancomycin-sensitive *Enterococcus* spp.        9281     100                                                    99                                                 
    Vancomycin-resistant *Enterococcus faecium*     35       94                                                     97                                                 
  Females \<18 y^c^                                                                                                                                                    
   Gram-negative                                                                                                                                                       
  *  Escherichia coli*                              3872     41           99            97          91              98                          91           74        
  *  Klebsiella pneumoniae*                         281                   100           97          97              46                          98           92        
  *  Proteus mirabilis*                             264      80           100           89          96                                          94           88        
  *  Pseudomonas aeruginosa*                        71                    97                        100                                         100                    
  Gram-positive                                                                                                                                                        
  *  Enterococcus* spp.                             441      100                                                    100                                                
    Methicillin-sensitive *Staphylococcus aureus*   61                                              93              98                                       97        92
  Females 18--64 y^d^                                                                                                                                                  
   Gram-negative                                                                                                                                                       
  *  Citrobacter diversus*                          498                   100                       100             92                          100          99        
  *  Citrobacter freundii*                          91                    99                        97              96                          98           88        
  *  Enterobacter aerogenes*                        433                   96                        99              16                          100          100       
  *  Enterobacter cloacae*                          126                   91                        98              46                          98           86        
  *  Escherichia coli*                              29 180   57           99            97          84              98                          92           75        
  *  Klebsiella pneumoniae*                         3642                  100           97          86              38                          87           80        
  *  Proteus mirabilis*                             1486     84           100           94          96                                          97           91        
  *  Pseudomonas aeruginosa*                        109                   94                        84                                          95                     
  *  Serratia marcescens*                           67                    100                       100                                         88           97        
  Gram-positive                                                                                                                                                        
    Methicillin-sensitive *Staphylococcus aureus*   430                                             92              98                                       99        87
    Methicillin-resistant *Staphylococcus aureus*   105                                             54              94                                       98        65
    Vancomycin-sensitive *Enterococcus* spp.        4425     100                                                    99                                                 
  Females \>64 y^e^                                                                                                                                                    
   Gram-negative                                                                                                                                                       
  *  Citrobacter diversus*                          190                   98                        98              86                          99           97        
  *  Citrobacter freundii*                          140                   91                        93              97                          100          88        
  *  Enterobacter aerogenes*                        154                   88                        100             55                          100          99        
  *  Enterobacter cloacae*                          123                   92                        98              47                          96           88        
  *  Escherichia coli*                              13 156   53           99            92          67              96                          88           71        
  *  Klebsiella pneumoniae*                         2781                                            46              21                          43           34        
  *  Proteus mirabilis*                             978      76           99            88          84                                          95           83        
  *  Pseudomonas aeruginosa*                        312                   97                        85                                          98                     
  *  Serratia marcescens*                           37                    100                       97                                          86           100       
  Gram-positive                                                                                                                                                        
    Methicillin-sensitive *Staphylococcus aureus*   106                                             74              98                                       100       91
    Methicillin-resistant *Staphylococcus aureus*   79                                              11              99                                       94        94
    Vancomycin-sensitive *Enterococcus* spp.        1843     100                                                    98                                                 
  Males \<18 y^f^                                                                                                                                                      
   Gram-negative                                                                                                                                                       
  *  Escherichia coli*                              126      52           99            94          91              98                          92           72        
  *  Klebsiella pneumoniae*                         21                    100           97          99              46                          100          91        
  *  Proteus mirabilis*                             108      70           100           86          96                                          93           85        
  Gram-positive                                                                                                                                                        
    Vancomycin-sensitive *Enterococcus* spp.        124      99                                                     100                                                
  Males 18--64 y^g^                                                                                                                                                    
   Gram-negative                                                                                                                                                       
  *  Citrobacter diversus*                          96                    100                       100             95                          100          100       
  *  Enterobacter aerogenes*                        83                    87                        98              30                          100          94        
  *  Enterobacter cloacae*                          34                    97                        94              38                          97           88        
  *  Escherichia coli*                              1862     48           99            96          70              97                          85           69        
  *  Klebsiella pneumoniae*                         318                   100           98          99              41                          99           94        
  *  Proteus mirabilis*                             157      72           99            85          83                                          93           80        
  *  Pseudomonas aeruginosa*                        139                   93                        65                                          93                     
  *  Serratia marcescens*                           54                    100                       98                                          89           96        
  Gram-positive                                                                                                                                                        
    Methicillin-sensitive *Staphylococcus aureus*   68                                              84              100                                      97        93
    Vancomycin-sensitive *Enterococcus* spp.        990      100                                                    99                                                 
  Males \>64 y^h^                                                                                                                                                      
   Gram-negative                                                                                                                                                       
  *  Citrobacter diversus*                          104                   100                       97              88                          99           97        
  *  Citrobacter freundii*                          49                    86                        96              90                          94           72        
  *  Enterobacter aerogenes*                        93                    89                        97              23                          100          99        
  *  Enterobacter cloacae*                          91                    89                        85              37                          93           81        
  *  Escherichia coli*                              2704     43           98            92          51              94                          82           64        
  *  Klebsiella pneumoniae*                         691                   100           98          95              45                          97           92        
  *  Proteus mirabilis*                             396      74           98            87          75                                          92           82        
  *  Pseudomonas aeruginosa*                        405                   92                        66                                          93                     
  *  Serratia marcescens*                           90                    100                       97                                          90           97        
  Gram-positive                                                                                                                                                        
    Methicillin-sensitive *Staphylococcus aureus*   145                                             70              99                                       98        94
    Methicillin-resistant *Staphylococcus aureus*   110                                             7               99                                       96        92
    Vancomycin-sensitive *Enterococcus* spp.        1458     100                                                    99                                                 

The 17 New York counties are Albany, Bronx, Dutchess, Fulton, Greene, Kings, Nassau, New York, Orange, Putnam, Queens, Richmond, Rockland, Suffolk, Sullivan, Ulster, and Westchester.

Abbreviations: Pip-Tazo, piperacillin-tazobactam; TMP-SMX, trimethoprim/sulfamethoxazole.

^a^N = total number of antimicrobial testing results.

^b^Data not shown for 1739 coagulase-negative staphylococci.

Organisms not reported due to \<30 isolates in the reporting group:

^c^Females \<18 years: *Citrobacter diversus* (29 isolates), *Citrobacter freundii* (11), *Enterobacter aerogenes* (19), *Enterobacter cloacae* (27), methicillin-resistant *S. aureus* (5), *Providencia rettgeri* (1), *Serratia marcescens* (7), *Staphylococcus haemolyticus* (9), *Staphylococcus hominis* spp. *hominis* (4), *Staphylococcus ludgunensis* (1), *Staphylococcus simulans* (25), *Stenotrophomonas maltophila* (2), vancomycin-resistant *Enterococcus faecium* (0).

^d^Females 18--64 years: *Providencia rettgeri* (5), *Providencia stuartii* (4), *Staphylococcus hominis* spp. *hominis* (9), *Staphylococcus ludgunensis* (29), *Stenotrophomonas maltophila* (8), vancomycin-resistant *Enterococcus faecium* (3).

^e^Females \>64 years: *Providencia rettgeri* (16), *Providencia stuartii* (13), *Staphylococcus hominis* spp. *hominis* (10), *Staphylococcus ludgunensis* (25), *Staphylococcus simulans* (28), *Stenotrophomonas maltophila* (10), vancomycin-resistant *Enterococcus faecium* (11).

^f^Males \<18 years: *Citrobacter diversus* (16), *Citrobacter freundii* (4), *Enterobacter aerogenes* (3), *Enterobacter cloacae* (3), *Klebsiella pneumoniae* (21), methicillin-resistant *S. aureus* (0), methicillin-sensitive *S. aureus* (15), *Providencia rettgeri* (1), *Pseudomonas aeruginosa* (15), *Serratia marcescens* (9), *Staphylococcus haemolyticus* (9), *Staphylococcus hominis* spp. *hominis* (3), *Staphylococcus ludgunensis* (0), *Staphylococcus simulans* (24), *Stenotrophomonas maltophila* (1), vancomycin-resistant *Enterococcus faecium* (0).

^g^Males 18--64 years: *Citrobacter freundii* (21), methicillin-resistant *S. aureus* (27), *Providencia rettgeri* (2), *Providencia stuartii* (2), *Staphylococcus hominis* spp. *hominis* (11), *Staphylococcus ludgunensis* (7), *Staphylococcus simulans* (1), *Stenotrophomonas maltophila* (8), vancomycin-resistant *Enterococcus faecium* (2).

^h^Males \>64 years: *Providencia rettgeri* (18), *Providencia stuartii* (13), *Staphylococcus hominis* spp. *hominis* (28), *Staphylococcus ludgunensis* (25), *Staphylococcus simulans* (16), *Stenotrophomonas maltophila* (24), vancomycin-resistant *Enterococcus faecium* (19).

Urine pathogens were isolated from bi-plates of Trypticase Soy Agar with 5% Sheep Blood (TSA II) and MacConkey II Agar, followed by identification and automated drug susceptibility testing (Vitek-2). Antimicrobials tested included ampicillin, ceftazidime, cefazolin, ciprofloxacin, nitrofurantoin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, tetracycline, oxacillin, and vancomycin, as appropriate. Minimum inhibitory concentration (MIC) susceptibility interpretations were derived from CLSI M100 S-25 \[[@CIT0006]\]. Antibiotic sensitivity percentages are reported as number of susceptible isolates divided by number of isolates tested. Susceptibility was reported overall and by sex and age (children: ≤17 years; adults: 18--64 years; and older adults: ≥65 years). Chi-square tests or Fisher exact tests were used to compare the overall prevalence of bacterial resistance within and between agents tested and between age and sex groups.

RESULTS {#s2}
=======

A total of 78 078 urine culture susceptibility reports were included ([Table 1](#T1){ref-type="table"}). The majority of the urine cultures were obtained from female patients. The most frequently recovered isolates were *Escherichia coli*, 65.1%; *Enterococcus* spp., 11.9%; and *Klebsiella pneumoniae*, 10.0%. Among isolates recovered from females, the distribution was consistent with the overall study population. In men, the prevalence of *E. coli* was lower (40.3 %) relative to the overall population, whereas the prevalence of *Enterococcus* was higher (22.1%). In children, *E. coli* was the most prevalent isolate (73.7%), followed by *Enterococcus* (10.4%) and *Proteus* species (6.8%). The distribution of pathogens in adult (age 18--64 years) patients was similar to the overall population: *E. coli* (68.5%), *Enterococcus* (11.2%), and *K. pneumoniae* (8.7%). In older adults, the prevalence of *E. coli* was lower (58.7%), whereas the prevalence rates of *Enterococcus* and *Klebsiella* were higher (12.2% and 12.8%, respectively).

Of all the isolates tested for nitrofurantoin sensitivity (n = 73 191), 90.4% were susceptible. Nitrofurantoin resistance was more commonly noted in males as compared with females (10.6% vs 9.1%, *P* \< .001) and older adults as compared with all other ages combined (12.3% vs 8.1%, *P* \< .001). High overall rates of susceptibility were reported for isolates tested for cefazolin sensitivity (90.4%). However, due to the high prevalence of *Enterococcus* spp. (which is intrinsically resistant to cefazolin), cefazolin only has activity against 68.2% of the isolates. Only 77.2% of all isolates tested (n = 67711) were trimethoprim-sulfamethoxazole susceptible. Resistance to trimethoprim-sulfamethoxazole was more prevalent in men than women (26.3% vs 22.7%, *P* \< .001) and in older adults than all other age groups combined (25.1% vs 22.1%, *P* \< .001). Of the isolates tested for ciprofloxacin sensitivity (n = 68 709), 80.2% were susceptible. Resistance to ciprofloxacin was more frequent in males than females (35.0% vs 17.3%, *P* \< .001) and in older adults than in all other ages combined (30. % vs 14.0%, *P* \< .001). Additional data on pathogen-specific sensitivity overall and by sex and age groups are presented in [Table 1](#T1){ref-type="table"}. County-specific data are provided in the [Supplementary Data](#sup1 sup2 sup3 sup4 sup5){ref-type="supplementary-material"}.

DISCUSSION {#s3}
==========

The current Infectious Disease Society of America (IDSA) guidelines for acute uncomplicated cystitis recommend nitrofurantoin, trimethoprim-sulfamethoxazole, or fosfomycin as firstline agents for treatment \[[@CIT0002]\]. Overall, we found that bacterial isolates in the outpatient setting in New York State were 90% sensitive *in vitro* to nitrofurantoin. The high probability of *in vitro* activity with nitrofurantoin is likely due to the high prevalence and susceptibility rates for *E. coli*. Although the IDSA guidelines do not define a resistance prevalence threshold for assessing the appropriateness of nitrofurantoin for empiric use in treating acute uncomplicated cystitis, if we apply the trimethoprim-sulfamethoxazole threshold (20%, per the IDSA guidelines), our data support the utilization of nitrofurantoin in the New York State outpatient setting for this condition. In contrast, trimethoprim-sulfamethoxazole appears to have more limited utility as an empiric treatment regimen for acute uncomplicated cystitis as the overall prevalence of trimethoprim-sulfamethoxazole resistance exceeded 20%. Unfortunately, fosfomycin susceptibility data were unavailable in this data set as testing was not routinely performed. Given the limited activity of trimethoprim-sulfamethoxazole and ciprofloxacin for acute uncomplicated cystitis, it would be prudent for laboratories to consider testing of fosfomycin in urinary isolates, especially for *Escherichia coli* and *Enterococcus faecalis*. In species other than *Escherichia coli* and *Enteroccocus faecalis*, the utility and validity of susceptibility results for fosfomycin have yet to be determined \[[@CIT0006]\]. Importantly, recent data show that 1 day of fosfomycin is inferior to 5 days of nitrofurantoin for acute uncomplicated cystitis \[[@CIT0007]\]. As such, fosfomycin should be used with caution when treating acute uncomplicated cystitis.

Susceptibility results from this study were also unfavorable to the empiric use of fluoroquinolones and β-lactam antibiotics. The overall prevalence of ciprofloxacin resistance was 19.8%, exceeding the IDSA-recommended 10% resistance threshold for empiric use. In light of the relatively high prevalence of fluoroquinolone resistance as well as growing concerns about fluoroquinolone-associated disability, our study supports the recent Food and Drug Administration recommendation to avoid empiric fluoroquinolone use unless no other alternative agents are available \[[@CIT0007]\]. We also examined cefazolin as a surrogate for cephalexin susceptibility. When only Gram-negative bacterial species were isolated, cefazolin appeared to be an appropriate empiric agent. However, the utility of cefazolin as an empiric agent is less than favorable due to the high prevalence of *Enterococcus*, an organism that is intrinsically resistant to cefazolin. Given that β-lactam medications require longer duration of treatment as compared with other therapies and are associated with lower efficacy \[[@CIT0008]\], our data suggest that β-lactam drugs should be considered as empiric agents only when potential benefits outweigh risks.

These data also indicate that the overall antimicrobial susceptibility percentages of antimicrobials are significantly lower for individuals in the ≥65 age group compared with all other ages combined and among males of all ages compared with females. These findings highlight the need to not rely exclusively on overall susceptibility results and to consider sex, age, and prior urine culture results when selecting an agent for a given patient. As susceptibility rates varied by age and sex, subsequent adjustment of therapy based on individualized culture and susceptibility reports should be performed in an effort to promote use of narrow-spectrum antibiotics where possible.

There are several caveats to be considered with respect to these findings. We did not include coagulase-negative staphylococci in this analysis due to its questionable pathogenicity. However, our conclusions would be affected minimally by the inclusion of coagulase-negative staphylococci because coagulase-negative staphylococci only accounted for 2% of isolates. Another potential limitation of this study is lack of data on clinical presentation of the patients. We did not determine whether these were symptomatic urinary tract infections or asymptomatic bacteriuria. Last, this study may overrepresent antimicrobial resistance rates as practitioners may only send urine cultures for patients with recurrent infections or treatment failure.

Although these data are from New York State, there are several generalizable aspects of this study. First, this project highlights the framework for creating a regional antibiogram. Regional antibiograms are important tools that could be used by health departments and other regional authorities to help influence prescribing and/or track antimicrobial resistance for key pathogens. Second, New York State (especially Kings, Queens, New York, Bronx, and Richmond counties, the 5 New York City counties) is unique in that it has an incredibly high population density \[[@CIT0009]\]. Along with antimicrobial utilization, population density has been shown to be associated with antimicrobial resistance prevalence \[[@CIT0010]\]. Hence, it stands to reason that New York State can be thought of as a regional bellwether for antimicrobial resistance.

In summary, we conducted a 1-year retrospective analysis of outpatient urine isolates collected from patients in New York State. Data indicated that nitrofurantoin has retained activity against many of the urinary pathogens since the publication of the 2011 IDSA guidelines and has a high prevalence of *in vitro* activity. In contrast, we found that the overall prevalence of resistance in bacterial urinary isolates exceeded the predefined IDSA empiric therapy thresholds of 20% for trimethoprim-sulfamethoxazole and 10% for fluoroquinolones, with resistance rates being highest in patients ≥65 years. These data highlight the need in outpatient settings for (1) urinary culture specimen submission, (2) antimicrobial stewardship efforts, and (3) assembly of local susceptibility data to guide empiric therapy in acute uncomplicated cystitis. Finally, these data also support the desperate need for new oral antimicrobials to treat acute uncomplicated cystitis in the outpatient setting.

Supplementary Data {#s4}
==================

Supplementary materials are available at *Open Forum Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
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